LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

Strona główna・Stock List・Gossamer Bio Inc

Gossamer Bio Inc

Closed

SectorHealthcare

0.17 -5.56

Buy Sell

Overview

Share price change

24h

Current

Min

0.17

Max

0.18

Key metrics
By Trading Economics
Income	574K -47M
Sales	3.2M 17M
EPS	-0.2
Profit margin	-275.223
Employees	161
EBITDA	1.2M -45M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+2700% upside

Dividends
By Dow Jones
Next Earnings	3 sie 2026

Market Stats
By TradingEconomics
Market Cap	-33M 46M
Previous open	5.73
Previous close	0.17

News Sentiment

By Acuity

64%

36%

289 / 344 Ranking in Healthcare

Gossamer Bio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 cze 2026, 21:51 UTC

Major Market Movers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 cze 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 cze 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 cze 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 cze 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 cze 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 cze 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 cze 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 cze 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 cze 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 cze 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 cze 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 cze 2026, 18:47 UTC

Acquisitions, Mergers, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 cze 2026, 18:38 UTC

Earnings

Money Quote: Tech Weakness in Context -- WSJ

4 cze 2026, 18:24 UTC

Earnings

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 cze 2026, 16:58 UTC

Earnings

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 cze 2026, 16:38 UTC

Earnings

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 cze 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 cze 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 cze 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Comparison

Price change

Gossamer Bio Inc Forecast

Price Target

By TipRanks

2700% upside

12 Months Forecast

Average 5.32 USD 2700%

High 15 USD

Low 0.28 USD

Based on 6 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.

Sentiment

By Acuity

289 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.